80_FR_36950 80 FR 36827 - National Institute of General Medical Sciences; Notice of Closed Meetings

80 FR 36827 - National Institute of General Medical Sciences; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 123 (June 26, 2015)

Page Range36827-36828
FR Document2015-15659

Federal Register, Volume 80 Issue 123 (Friday, June 26, 2015) 
[Federal Register Volume 80, Number 123 (Friday, June 26, 2015)]
[Notices]
[Pages 36827-36828]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-15659]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; Medical Scientist Training Program 
Grants.
    Date: July 14, 2015.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Natcher Building, 45 
Center Drive, Room 3An.12, Bethesda, MD 20892, (Telephone Conference 
Call).
    Contact Person: Rebecca H. Johnson, Ph.D., Scientific Review 
Officer, Office of Scientific Review, National Institute of General 
Medical Sciences, National Institutes of Health, 45 Center Drive, 
Room 3An.18C, Bethesda, MD 20892, 301-594-2771, 
[email protected].

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis

[[Page 36828]]

Panel Review of R25 Research Training Grant Applications.
    Date: July 17, 2015.
    Time: 8:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue, 
Chevy Chase, MD 20815
    Contact Person: Lisa A. Dunbar, Ph.D., Scientific Review 
Officer, Office of Scientific Review, National Institute of General 
Medical Sciences, National Institutes of Health, 45 Center Drive, 
Room 3An.12F, Bethesda, MD 20892, 301-594-2849, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives, National Institutes of Health, HHS)

    Dated: June 22, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-15659 Filed 6-25-15; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 80, No. 123 / Friday, June 26, 2015 / Notices 36827 for the prophylaxis and treatment of Complete applications for a license in Place: NIAAA, NIH, 5635 Fishers Lane, cancer.’’ an appropriate field of use that are filed Room CR2098, Rockville, MD 20852, in response to this notice will be treated (Telephone Conference Call). DATES: Only applications for a license Contact Person: Ranga Srinivas, Ph.D., which are received by the NIH Office of as objections to the grant of the Chief, Extramural Project Review Branch, Technology Transfer on or before July contemplated exclusive license. National Institute on Alcohol Abuse and 27, 2015 will be considered. Comments and objections submitted to Alcoholism, NIH, 5635 Fishers Lane, Room ADDRESSES: Requests for copies of the this notice will not be made available 2085, Rockville, MD 20852, (301) 451–2067, patent application, inquiries, comments, for public inspection and, to the extent srinivar@mail.nih.gov. permitted by law, will not be released (Catalogue of Federal Domestic Assistance and other materials relating to the under the Freedom of Information Act, Program Nos. 93.271, Alcohol Research contemplated exclusive license should Career Development Awards for Scientists be directed to: David A. Lambertson, 5 U.S.C. 552. and Clinicians; 93.272, Alcohol National Ph.D., Senior Licensing and Patenting Dated: June 22, 2015. Research Service Awards for Research Manager, Office of Technology Transfer, Richard U. Rodriguez, Training; 92.273, Alcohol Research Programs; National Institutes of Health, 6011 93.891, Alcohol Research Center Grants; Acting Director, Office of Technology Executive Boulevard, Suite 325, 93.701, ARRA Related Biomedical Research Transfer, National Institutes of Health. Rockville, MD 20852–3804; Telephone: and Research Supports Awards, National [FR Doc. 2015–15656 Filed 6–25–15; 8:45 am] Institutes of Health, HHS) (301) 435–4632; Facsimile: (301) 402– BILLING CODE 4140–01–P 0220; Email: lambertsond@mail.nih.gov. Dated: June 22, 2015. SUPPLEMENTARY INFORMATION: This Melanie J. Gray, invention concerns an anti-TSLPR DEPARTMENT OF HEALTH AND Program Analyst, Office of Federal Advisory (Thymic Stromal Lymphopoietin HUMAN SERVICES Committee Policy. Receptor) chimeric antigen receptor [FR Doc. 2015–15658 Filed 6–25–15; 8:45 am] (CAR) and methods of using the CAR for National Institutes of Health BILLING CODE 4140–01–P the treatment of TSLPR-expressing cancers, including B cell malignancies. National Institute on Alcohol Abuse TSLPR is a cell surface antigen that is and Alcoholism; Notice of Closed DEPARTMENT OF HEALTH AND preferentially expressed on certain types Meetings HUMAN SERVICES of cancer cells, particularly rare cancers of B cell origin such as acute Pursuant to section 10(d) of the National Institutes of Health lymphoblastic leukemia (ALL). The Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is National Institute of General Medical anti-TSLPR CARs of this technology Sciences; Notice of Closed Meetings contain (1) antigen recognition hereby given of the following meetings. sequences that bind specifically to The meetings will be closed to the Pursuant to section 10(d) of the TSLPR and (2) signaling domains that public in accordance with the Federal Advisory Committee Act, as can activate the cytotoxic functions of a provisions set forth in sections amended (5 U.S.C. App.), notice is T cell. The anti-TSLPR CAR can be 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., hereby given of the following meetings. transduced into T cells that are as amended. The grant applications and The meetings will be closed to the harvested from a cancer patient; from the discussions could disclose public in accordance with the there, T cells expressing the anti-TSLPR confidential trade secrets or commercial provisions set forth in sections CAR are selected, expanded and then be property such as patentable material, 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., reintroduced into the patient. Once the and personal information concerning as amended. The grant applications and anti-TSLPR CAR-expressing T cells are individuals associated with the grant the discussions could disclose reintroduced into the patient, the T cells applications the disclosure of which confidential trade secrets or commercial can selectively bind to TSLPR- would constitute a clearly unwarranted property such as patentable material, expressing cancer cells through its invasion of personal privacy. and personal information concerning antigen recognition sequences, thereby Name of Committee: National Institute on individuals associated with the grant activating the T cell through its Alcohol Abuse and Alcoholism Special applications, the disclosure of which signaling domains to selectively kill the Emphasis Panel; NIAAA Review of Member would constitute a clearly unwarranted cancer cells. Through this mechanism of Conflict Applications (AA2). invasion of personal privacy. action, the selectivity of the a CAR Date: July 24, 2015. Name of Committee: National Institute of allows the T cells to kill cancer cells Time: 1:00 a.m. to 4:00 p.m. General Medical Sciences Special Emphasis Agenda: To review and evaluate grant Panel; Medical Scientist Training Program while leaving healthy, essential cells applications. unharmed. This can result in an Grants. Place: NIAAA, NIH, 5635 Fishers Lane, Date: July 14, 2015. effective therapeutic strategy with fewer Room CR2098, Rockville, MD 20852, Time: 1:00 p.m. to 5:00 p.m. side effects due to less non-specific (Telephone Conference Call). Agenda: To review and evaluate grant killing of cells. Contact Person: Ranga Srinivas, Ph.D., applications. The prospective exclusive license will Chief, Extramural Project Review Branch, Place: National Institutes of Health, be royalty bearing and will comply with National Institute on Alcohol Abuse and Natcher Building, 45 Center Drive, Room the terms and conditions of 35 U.S.C. Alcoholism, NIH, 5635 Fishers Lane, Room 3An.12, Bethesda, MD 20892, (Telephone 209 and 37 CFR part 404. The 2085, Rockville, MD 20852, (301) 451–2067, Conference Call). prospective exclusive license may be srinivar@mail.nih.gov. Contact Person: Rebecca H. Johnson, Ph.D., Name of Committee: National Institute on Scientific Review Officer, Office of Scientific tkelley on DSK3SPTVN1PROD with NOTICES granted unless the NIH receives written Alcohol Abuse and Alcoholism Special Review, National Institute of General Medical evidence and argument that establishes Sciences, National Institutes of Health, 45 Emphasis Panel; NIAAA Neuroscience that the grant of the license would not Member Conflict Applications. Center Drive, Room 3An.18C, Bethesda, MD be consistent with the requirements of Date: July 29, 2015. 20892, 301–594–2771, johnsonrh@ 35 U.S.C. 209 and 37 CFR part 404 Time: 1:00 p.m. to 4:00 p.m. nigms.nih.gov. within thirty (30) days from the date of Agenda: To review and evaluate grant Name of Committee: National Institute of this published notice. applications. General Medical Sciences Special Emphasis VerDate Sep<11>2014 18:15 Jun 25, 2015 Jkt 235001 PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 E:\FR\FM\26JNN1.SGM 26JNN1

36828 Federal Register / Vol. 80, No. 123 / Friday, June 26, 2015 / Notices Panel Review of R25 Research Training Grant [HHS Ref. E–039–2011/0–CA–04]; cells. Moreover, as these antibodies Applications. European Patent Application No. selectively target ROR1, they can also be Date: July 17, 2015. 11791733.6 entitled, ‘‘Chimeric rabbit/ used to diagnose B-cell malignancies. Time: 8:30 a.m. to 5:00 p.m. human ROR1 antibodies’’ filed The prospective exclusive license will Agenda: To review and evaluate grant November 30, 2011 [HHS Ref. E–039– comply with the terms and conditions applications. Place: Courtyard by Marriott Chevy Chase, 2011/0–EP–05]; and U.S. Patent of 35 U.S.C. 209 and 37 CFR part 404. 5520 Wisconsin Avenue, Chevy Chase, MD Application No. 13/990,977 entitled, The exclusive license may be granted 20815 ‘‘Chimeric rabbit/human ROR1 unless within thirty (30) days from the Contact Person: Lisa A. Dunbar, Ph.D., antibodies’’ filed May 31, 2013 [HHS date of this published notice, the NIH Scientific Review Officer, Office of Scientific Ref. E–039–2011/0–US–06] and all receives written evidence and argument Review, National Institute of General Medical related continuing and foreign patents/ that establishes that the grant of the Sciences, National Institutes of Health, 45 patent applications for the technology license would not be consistent with the Center Drive, Room 3An.12F, Bethesda, MD family to Emergent BioSolutions. The requirements of 35 U.S.C. 209 and 37 20892, 301–594–2849, dunbarl@mail.nih.gov. patent rights in these inventions have CFR part 404. (Catalogue of Federal Domestic Assistance been assigned to the Government of the Any additional, properly filed, and Program Nos. 93.375, Minority Biomedical complete applications for a license in United States of America. Research Support; 93.821, Cell Biology and The prospective exclusive license the field of use filed in response to this Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry territory may be worldwide and the notice will be treated as objections to Research; 93.862, Genetics and field of use may be limited to the use the grant of the contemplated exclusive Developmental Biology Research; 93.88, of the Licensed Patent Rights to license. Comments and objections Minority Access to Research Careers; 93.96, develop, make, have made, sell, have submitted to this notice will not be Special Minority Initiatives, National sold, import and export bi-specific and made available for public inspection Institutes of Health, HHS) multi-specific fusion proteins that are and, to the extent permitted by law, will Dated: June 22, 2015. capable of eliciting redirected T-cell not be released under the Freedom of Melanie J. Gray, cytotoxicity for the treatment of human Information Act, 5 U.S.C. 552. Program Analyst, Office of Federal Advisory receptor tyrosine kinase-like orphan Dated: June 22, 2015. Committee Policy. receptor 1 (ROR1) expressing cancers, Richard U. Rodriguez, [FR Doc. 2015–15659 Filed 6–25–15; 8:45 am] wherein said fusion proteins comprise Acting Director, Office of Technology one or more single-chain variable Transfer, National Institutes of Health. BILLING CODE 4140–01–P fragment (scFv) ROR1 binding domains [FR Doc. 2015–15655 Filed 6–25–15; 8:45 am] from the anti-ROR1 antibodies BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND designated as R11 or R12, one or more HUMAN SERVICES of Licensee’s proprietary scFv CD3 binding domains, and optionally a DEPARTMENT OF HEALTH AND National Institutes of Health fragment crystallizable (Fc) domain. HUMAN SERVICES DATES: Only written comments and/or Prospective Grant of an Exclusive applications for a license which are National Institutes of Health License Agreement: Development of received by the NIH Office of Bispecific and Multi-Specific Fusion Technology Transfer on or before July Prospective Grant of Exclusive Proteins for the Treatment of ROR1 27, 2015 will be considered. License: The Development of an Anti- Expressing Human Cancers ADDRESSES: Requests for copies of the CD19 Chimeric Antigen Receptor AGENCY: National Institutes of Health, patent applications, inquiries, (CAR) for the Treatment of Human HHS. comments, and other materials relating Cancers ACTION: Notice. to the contemplated exclusive AGENCY: National Institutes of Health, evaluation option license should be HHS. SUMMARY: This is notice, in accordance directed to: Jennifer Wong, M.S., Senior ACTION: Notice. with 35 U.S.C. 209 and 37 CFR part 404, Licensing and Patenting Manager, Office that the National Institutes of Health, of Technology Transfer, National SUMMARY: This is notice, in accordance Department of Health and Human Institutes of Health, 6011 Executive with 35 U.S.C. 209 and 37 CFR part 404, Services, is contemplating the grant of Boulevard, Suite 325, Rockville, MD that the National Institutes of Health, an exclusive license agreement to 20852–3804; Telephone: (301) 435– Department of Health and Human practice the inventions embodied in US 4633; Facsimile: (301) 402–0220; Email: Services, is contemplating the grant of Provisional Application No. 61/418,550 wongje@od.nih.gov. an exclusive license to practice the entitled, ‘‘Chimeric rabbit/human ROR1 SUPPLEMENTARY INFORMATION: Tyrosine inventions embodied in U.S. Provisional antibodies’’ filed December 1, 2010 kinase-like orphan receptor 1 (ROR1) is Patent Application 62/006,313 entitled [HHS Ref. E–039–2011/0–US–01]; PCT a signature cell surface antigen for B-cell ‘‘Chimeric Antigen Receptors Targeting Application No. PCT/US2011/062670 malignancies, most notably, B-cell CD–19’’ [HHS Ref. E–042–2014/0–US– entitled, ‘‘Chimeric rabbit/human ROR1 chronic lymphocytic leukemia (B–CLL) 01], and all related continuing and antibodies’’ filed November 30, 2011 and mantle cell lymphoma (MCL) cells, foreign patents/patent applications for [HHS Ref. E–039–2011/0–PCT–02]; two incurable diseases. The the technology family, to Kite Pharma, Australian Patent Application No. investigators have developed a portfolio Inc. The patent rights in these tkelley on DSK3SPTVN1PROD with NOTICES 2011336650 entitled, ‘‘Chimeric rabbit/ of chimeric anti-ROR1 monoclonal inventions have been assigned to and/or human ROR1 antibodies’’ filed antibodies that selectively target ROR1 exclusively licensed to the Government November 30, 2011 [HHS Ref. E–039– malignant B-cells but not normal B- of the United States of America. 2011/0–AU–03]; Canadian Patent cells. These antibodies may be linked to The prospective exclusive licensed Application No. 2818992 entitled, chemical drugs or biological toxins thus territory may be worldwide, and the ‘‘Chimeric rabbit/human ROR1 providing targeted cytotoxic delivery to field of use may be limited to: ‘‘All antibodies’’ filed November 30, 2011 malignant B-cells while sparing normal prophylactic and therapeutic uses for VerDate Sep<11>2014 18:15 Jun 25, 2015 Jkt 235001 PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 E:\FR\FM\26JNN1.SGM 26JNN1


Document Created: 2015-12-15 14:14:35
Document Modified: 2015-12-15 14:14:35
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesJuly 14, 2015.
FR Citation80 FR 36827 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR